title: [Thrombosis of the sinus durae matris as a complication of therapy in patients with Hodgkin lymphoma].
abstract: OBJECTIVE
  To describe thrombosis of the sinus durae matris (TSDM) in lymphomas.
  
  
  METHODS
  402 patients with Hodgkin lymphoma were treated using the BEACOPP-14 protocol in 2006 to 2013. Thrombotic events occurred in 6% of the patients, including 3 (0.8%) who developed brain magnetic resonance imaging-verified TSDM.
  
  
  RESULTS
  TSDM developed in 3 women aged 17, 18, and 25 years during 3-6 chemotherapy cycles involving glucocorticosteroids in a dose of 80 mg/m2 on days 1-7 and an oral contraceptive used continuously for 1.5-3 months. The symptoms of thrombosis were severe headache; 2 patients had convulsive syndrome with short-term loss of consciousness. Anticoagulant therapy with intravenous heparin 20,000--24,000 U/day led to thrombus recanalization within 4-10 days. No rethromoboses were observed during a subsequent follow-up.
  
  
  CONCLUSIONS
  The BEACOPP-14 treatment in young women with Hodgkin lymphoma who continuously take oral contraceptives should be combined with anticoagulant therapy, by monitoring their coagulogram.
authors.forename: I V
authors.initials: IV
authors.lastname: Shitareva
authors.forename: T N
authors.initials: TN
authors.lastname: Moiseeva
authors.forename: L S
authors.initials: LS
authors.lastname: Al'-Radi
authors.forename: O V
authors.initials: OV
authors.lastname: Margolin
authors.forename: A B
authors.initials: AB
authors.lastname: Khlavno
authors.forename: G A
authors.initials: GA
authors.lastname: Iatsyk
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
mesh_terms: D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003392:Cranial Sinuses / Q000187:drug effects / Q000473:pathology; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D012851:Sinus Thrombosis, Intracranial / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin